SA

Sebastian Anastassiou

Investing in need-driven health tech founders

Barcelona, Catalonia

Invests in

Stages:

Locations:

  • Min Investment:

    $10,000,000.00
  • Max Investment:

    $50,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • Principal, Head of Investments

    2022

    Investing in need-driven health tech founders building the future of information-driven healthcare.

  • Investment Manager

    2021 - 2022

  • Associate

    2020 - 2021

  • MBA Associate

    2020 - 2020

  • Board Member

    2024

    Empowering providers with easy access to outside medical records and targeted clinical insights Driving better outcomes for patients.

  • Board Member

    2022

    Segmed partners with health systems and other medical providers to provide curated and anonymized data for medical AI companies to facilitate and accelerate algorithm development.

  • Board Observer

    2021

    Promptly is defined by this anxiety of fundamentally changing how health is perceived by patients and how healthcare is structured and delivered by providers.

  • Board Member

    2021

    EarlySight is developing a medical device to help doctors detect and treat eye diseases at an early-stage thanks to precise retinal imaging.

  • Board Observer

    2020 - 2021

  • Board Member

    2021

    Contextflow's mission is o empower radiologists to complete their daily workload faster and with higher quality and cost-efficiency by delivering a unique and scalable AI backbone that fully integrates into clinical workflows.

2022 - 2024

  • Board Member

    2022 - 2024

    Formulator Ltd is a Finnish company providing a solution for mental health case formulations as a service to both individuals and professionals. Formulator has modelled research evidence and decades of clinical expertise behind a conversational agent. The individual’s dialogue with the agent produces a case formulation, MyTarina, that is shared with the clinician.

2023 - 2024

  • Board Member

    2023 - 2024

    Terapet's vision is that their innovative solutions will be an integral part of the next generation proton therapy - safer, more precise, faster and available for the wider public.

2020 - 2022

  • Board Observer

    2020 - 2022

    Replica Analytics develops unique technologies for generating privacy protective synthetic data that maintains the statistical properties of real data, enabling fast and effective access to high utility data while meeting regulatory obligations. The team has developed technology specific to the complexities of longitudinal health data. Replica was acquired by Aetion.

2019 - 2021

  • MBA Candidate 2021

    2019 - 2021

    - Concentration in Entrepreneurship & Innovation - VP of Startup & Entrepreneurship Club - Managing the Barcelona Technology Transfer Group (BTTG) program - Consultant for Healthcare startups